Proundly Supported by
Pfizer Foundation
    Home | Current Issue | Past Issue | Board | Instruction | Contact


The Efficacy of Combined Low Dose of Allopurinol and Benzbromarone Compared to Standard Dose of Allopurinol in Hyperuricemia

1087

Somchai Akkasilpa MD*, Manathip Osiri MD*,
Utis Deesomchok MD*, Yingyos Avihingsanon MD*

* Department of Medicine, Faculty of Medicine, Chulalongkorn University

Abstract


Objective : To compare the efficacy of combined low dose of hypouricemic drugs (Allopurinol 100 mg and benzbromarone 20 mg; Allomaron®) and standard dose 300 mg of allopurinol in hyperuricemia.
Material and Method : A prospective, open study of 94 hyperuricemic patients was done at King Chulalongkorn Memorial Hospital. Each group of 47 patients was given a combined low dose of hypouricemic drugs (Allopurinol 100 mg and benzbromarone 20 mg; Allomaron®) and a standard dose 300 mg of allopurinol. Serum uric acid was measured before and 4 weeks after receiving the drugs. The efficacy was measured from the difference of the level of serum uric acid before and after receiving the drugs.
Results : The patients receiving the combined low dose of hypouricemic drugs and standard dose of allopurinol showed a mean reduction of serum uric acid of 2.5 + 3.4 mg/dl and 4.1 + 2.7 mg/dl consecutively. There was a statistically significant difference between the 2 groups (P = 0.010).
Conclusion : This study demonstrates that the efficacy of standard dose 300 mg of allopurinol is superior to a combined low dose of allopurinol and benzbromarone in lowering the level of serum uric acid level.

Keyword : Allopurinol, Benzbromarone, Allomaron, Hyperuricemia



Download Full Paper
  Vol87_No9_1087.pdf  [ 70.46 Kb]

Home | Current Issue | Past Issue | Board | Instruction | Contact

© Copyright The Medical Association of Thailand. All Rights Reserved.2001-2002